Novel Polymorphic Cocrystals of the Non-Steroidal Anti-Inflammatory Drug Niflumic Acid: Expanding the Pharmaceutical Landscape.

dc.contributor.authorAcebedo-Martínez, Francisco Javier
dc.contributor.authorAlarcón-Payer, Carolina
dc.contributor.authorFrontera, Antonio
dc.contributor.authorBarbas, Rafael
dc.contributor.authorProhens, Rafel
dc.contributor.authorDi Crisci, Milena
dc.contributor.authorDomínguez-Martín, Alicia
dc.contributor.authorGómez-Morales, Jaime
dc.contributor.authorChoquesillo-Lazarte, Duane
dc.date.accessioned2025-01-07T14:22:21Z
dc.date.available2025-01-07T14:22:21Z
dc.date.issued2021-12-13
dc.description.abstractAny time the pharmaceutical industry develops a new drug, potential polymorphic events must be thoroughly described, because in a crystalline pharmaceutical solid, different arrangements of the same active pharmaceutical ingredient can yield to very different physicochemical properties that might be crucial for its efficacy, such as dissolution, solubility, or stability. Polymorphism in cocrystal formulation cannot be neglected, either. In this work, two different cocrystal polymorphs of the non-steroidal anti-inflammatory drug niflumic acid and caffeine are reported. They have been synthesized by mechanochemical methods and thoroughly characterized in solid-state by powder and single crystal X-ray diffraction respectively, as well as other techniques such as thermal analyses, infrared spectroscopy and computational methods. Both theoretical and experimental results are in agreement, confirming a conformational polymorphism. The polymorph NIF-CAF Form I exhibits improved solubility and dissolution rate compared to NIF-CAF Form II, although Form II is significantly more stable than Form I. The conditions needed to obtain these polymorphs and their transition have been carefully characterized, revealing an intricate system.
dc.identifier.doi10.3390/pharmaceutics13122140
dc.identifier.issn1999-4923
dc.identifier.pmcPMC8706418
dc.identifier.pmid34959421
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8706418/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/1999-4923/13/12/2140/pdf?version=1639980271
dc.identifier.urihttps://hdl.handle.net/10668/26326
dc.issue.number12
dc.journal.titlePharmaceutics
dc.journal.titleabbreviationPharmaceutics
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de las Nieves
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectNSAIDs
dc.subjectcaffeine
dc.subjectcocrystal polymorphism
dc.subjectmechanochemical synthesis
dc.subjectniflumic acid
dc.titleNovel Polymorphic Cocrystals of the Non-Steroidal Anti-Inflammatory Drug Niflumic Acid: Expanding the Pharmaceutical Landscape.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number13

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC8706418.pdf
Size:
7.52 MB
Format:
Adobe Portable Document Format